Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making strides in neurological health through a two-pronged strategy that combines an investigational therapy for multiple sclerosis (MS) with a proprietary dietary supplement aimed at mitigating the effects of alcohol. The company is developing Lucid-MS, a novel compound designed to target the enzyme PAD2, which plays a role in myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, offering a new avenue for addressing the underlying causes of the disease.
The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial for Lucid-MS. Supporting this effort is an imaging collaboration with Massachusetts General Hospital, which will help assess the drug's effects on myelin in the brain. This partnership underscores the scientific rigor behind Quantum BioPharma's approach and could accelerate the development of a therapy that may change the treatment landscape for MS patients.
In parallel, Quantum BioPharma is advancing unbuzzd, a dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover symptoms. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated the product's efficacy. unbuzzd was invented by Quantum BioPharma and spun out to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The dual focus on both a disease-modifying therapy for MS and a consumer health product highlights Quantum BioPharma's commitment to addressing neurological health from multiple angles. By targeting myelin repair in MS and offering a solution for alcohol-related impairment, the company is positioning itself in two growing markets. The progress of Lucid-MS through regulatory milestones and the commercial potential of unbuzzd could provide significant value for shareholders, while also addressing unmet medical needs.
For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. To read the full article, visit https://ibn.fm/Rl89U.
